246 related articles for article (PubMed ID: 32080788)
1. Ret Receptor Has Distinct Alterations and Functions in Breast Cancer.
Gattelli A; Hynes NE; Schor IE; Vallone SA
J Mammary Gland Biol Neoplasia; 2020 Mar; 25(1):13-26. PubMed ID: 32080788
[TBL] [Abstract][Full Text] [Related]
2. Expression of RET is associated with Oestrogen receptor expression but lacks prognostic significance in breast cancer.
Mechera R; Soysal SD; Piscuoglio S; Ng CKY; Zeindler J; Mujagic E; Däster S; Glauser P; Hoffmann H; Kilic E; Droeser RA; Weber WP; Muenst S
BMC Cancer; 2019 Jan; 19(1):41. PubMed ID: 30621641
[TBL] [Abstract][Full Text] [Related]
3. ER-positive breast cancer cells are poised for RET-mediated endocrine resistance.
Horibata S; Rice EJ; Mukai C; Marks BA; Sams K; Zheng H; Anguish LJ; Coonrod SA; Danko CG
PLoS One; 2018; 13(4):e0194023. PubMed ID: 29608602
[TBL] [Abstract][Full Text] [Related]
4. High expression of the RET receptor tyrosine kinase and its ligand GDNF identifies a high-risk subset of estrogen receptor positive breast cancer.
Kakati RT; Kim H; Whitman A; Spanheimer PM
Breast Cancer Res Treat; 2023 Jun; 199(3):589-601. PubMed ID: 37061618
[TBL] [Abstract][Full Text] [Related]
5. The Ret receptor tyrosine kinase pathway functionally interacts with the ERalpha pathway in breast cancer.
Boulay A; Breuleux M; Stephan C; Fux C; Brisken C; Fiche M; Wartmann M; Stumm M; Lane HA; Hynes NE
Cancer Res; 2008 May; 68(10):3743-51. PubMed ID: 18483257
[TBL] [Abstract][Full Text] [Related]
6. RET in breast cancer: functional and therapeutic implications.
Morandi A; Plaza-Menacho I; Isacke CM
Trends Mol Med; 2011 Mar; 17(3):149-57. PubMed ID: 21251878
[TBL] [Abstract][Full Text] [Related]
7. RET signaling in breast cancer therapeutic resistance and metastasis.
Pecar G; Liu S; Hooda J; Atkinson JM; Oesterreich S; Lee AV
Breast Cancer Res; 2023 Mar; 25(1):26. PubMed ID: 36918928
[TBL] [Abstract][Full Text] [Related]
8. RET rearrangements are actionable alterations in breast cancer.
Paratala BS; Chung JH; Williams CB; Yilmazel B; Petrosky W; Williams K; Schrock AB; Gay LM; Lee E; Dolfi SC; Pham K; Lin S; Yao M; Kulkarni A; DiClemente F; Liu C; Rodriguez-Rodriguez L; Ganesan S; Ross JS; Ali SM; Leyland-Jones B; Hirshfield KM
Nat Commun; 2018 Nov; 9(1):4821. PubMed ID: 30446652
[TBL] [Abstract][Full Text] [Related]
9. Targeting RET-interleukin-6 crosstalk to impair metastatic dissemination in breast cancer.
Morandi A; Isacke CM
Breast Cancer Res; 2014 Jan; 16(1):301. PubMed ID: 24467886
[TBL] [Abstract][Full Text] [Related]
10. Genetic and epigenetic factors affect RET gene expression in breast cancer cell lines and influence survival in patients.
Griseri P; Garrone O; Lo Sardo A; Monteverde M; Rusmini M; Tonissi F; Merlano M; Bruzzi P; Lo Nigro C; Ceccherini I
Oncotarget; 2016 May; 7(18):26465-79. PubMed ID: 27034161
[TBL] [Abstract][Full Text] [Related]
11. Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion.
Furugaki K; Mochizuki M; Kohno M; Shu S; Harada N; Yoshimura Y
BMC Cancer; 2019 Apr; 19(1):301. PubMed ID: 30943926
[TBL] [Abstract][Full Text] [Related]
12. Preclinical Efficacy and Safety Assessment of an Antibody-Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma.
Nguyen M; Miyakawa S; Kato J; Mori T; Arai T; Armanini M; Gelmon K; Yerushalmi R; Leung S; Gao D; Landes G; Haak-Frendscho M; Elias K; Simmons AD
Clin Cancer Res; 2015 Dec; 21(24):5552-62. PubMed ID: 26240273
[TBL] [Abstract][Full Text] [Related]
13. Reciprocal feedback regulation of ST3GAL1 and GFRA1 signaling in breast cancer cells.
Fan TC; Yeo HL; Hsu HM; Yu JC; Ho MY; Lin WD; Chang NC; Yu J; Yu AL
Cancer Lett; 2018 Oct; 434():184-195. PubMed ID: 30040982
[TBL] [Abstract][Full Text] [Related]
14. Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating
Rich TA; Reckamp KL; Chae YK; Doebele RC; Iams WT; Oh M; Raymond VM; Lanman RB; Riess JW; Stinchcombe TE; Subbiah V; Trevarthen DR; Fairclough S; Yen J; Gautschi O
Clin Cancer Res; 2019 Oct; 25(19):5832-5842. PubMed ID: 31300450
[TBL] [Abstract][Full Text] [Related]
15. Expression of the RET proto-oncogene is regulated by TFAP2C in breast cancer independent of the estrogen receptor.
Spanheimer PM; Woodfield GW; Cyr AR; Kulak MV; White-Baer LS; Bair TB; Weigel RJ
Ann Surg Oncol; 2013 Jul; 20(7):2204-12. PubMed ID: 22878616
[TBL] [Abstract][Full Text] [Related]
16. RET fusions in solid tumors.
Li AY; McCusker MG; Russo A; Scilla KA; Gittens A; Arensmeyer K; Mehra R; Adamo V; Rolfo C
Cancer Treat Rev; 2019 Dec; 81():101911. PubMed ID: 31715421
[TBL] [Abstract][Full Text] [Related]
17. GGA3-mediated recycling of the RET receptor tyrosine kinase contributes to cell migration and invasion.
Crupi MJF; Maritan SM; Reyes-Alvarez E; Lian EY; Hyndman BD; Rekab AN; Moodley S; Antonescu CN; Mulligan LM
Oncogene; 2020 Feb; 39(6):1361-1377. PubMed ID: 31645646
[TBL] [Abstract][Full Text] [Related]
18. Identification and characterization of RET fusions in advanced colorectal cancer.
Le Rolle AF; Klempner SJ; Garrett CR; Seery T; Sanford EM; Balasubramanian S; Ross JS; Stephens PJ; Miller VA; Ali SM; Chiu VK
Oncotarget; 2015 Oct; 6(30):28929-37. PubMed ID: 26078337
[TBL] [Abstract][Full Text] [Related]
19. Chronic expression of wild-type Ret receptor in the mammary gland induces luminal tumors that are sensitive to Ret inhibition.
Gattelli A; García Solá ME; Roloff TC; Cardiff RD; Kordon EC; Chodosh LA; Hynes NE
Oncogene; 2018 Jul; 37(29):4046-4054. PubMed ID: 29695833
[TBL] [Abstract][Full Text] [Related]
20. MiR-182 promotes cancer invasion by linking RET oncogene activated NF-κB to loss of the HES1/Notch1 regulatory circuit.
Spitschak A; Meier C; Kowtharapu B; Engelmann D; Pützer BM
Mol Cancer; 2017 Jan; 16(1):24. PubMed ID: 28122586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
